MannKind (MNKD) Posts Q3 EPS of 26c, Topping Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
MannKind (MNKD) Enters Settlement Agreement with Sanofi (SNY)
November 9, 2016 5:12 PM ESTMannKind (NASDAQ: MNKD) disclosed the following on Wednesday night:
Item 1.01 Entry into a Material Definitive Agreement.
On November 9, 2016 (the Effective Date), MannKind Corporation (the Company), Technosphere International C.V. (TICV) and MannKind Netherlands B.V. (BV and together with the Company, TICV and their respective affiliates, the MannKind Entities) entered into a settlement agreement (the Settlement Agreement) with sanofi-aventis U.S. LLC (Sanofi, together with its affiliates, the Sanofi Entities).
Under the terms of the Settlement Agreement, Sanofi has agreed to purchase $10.2 million of insulin from the Company by December 3, 2016 under the insulin put option (the... More
